suggest that obstructive sleep apnea (OSA) is associated with an increased risk of cognitive impairment.
1,2 OSA, a prevalent condition in older adults with MCI and AD, 3 is characterized by episodic nocturnal airway collapse, reducing or stopping respiration and causing hypoxia and disturbed sleep. OSA is treated with continuous positive airway pressure (CPAP), a pressurized mask worn during sleep, but few studies have confirmed if treatment delays cognitive decline.
The aim of this pilot clinical trial (Memories 1) was to determine whether CPAP treatment adherence predicts cognitive and everyday function after 1 year in older adults with MCI and to determine ESs for a larger trial. We hypothesized that cognitive and everyday function would be improved.
METHODS Design
Although CPAP eliminates OSA, it must be consistently used for at least 4 hours per night for a therapeutic response, 4 and only 30% to 60% of individuals prescribed CPAP adhere to it. 5 An advantage of a design incorporating CPAP adherence is that CPAP systems record use. This quasi-experimental study had two comparison groups: (1) an MCI, OSA, and CPAP-adherent group (MCI +CPAP, ≥4 h mean CPAP use per night for 1 y); and (2) an MCI, OSA, CPAP-nonadherent group (MCI −CPAP, <4 h mean CPAP use per night for 1 y). We also recruited an MCI without OSA group (n = 15), but these results are not reported here. 6 The study was approved by the institutional review boards and registered with ClinicalTrials.gov (NCT01482351).
Settings and sample
Participants were identified primarily through sleep and geriatric clinics (Supplementary Figure S1) . Enrollment was from September 2012 through December 2014. The final sample at 1 year consisted of 54 older adults with MCI: (1) MCI +CPAP, n = 29; and (2) MCI −CPAP, n = 25. Data analysis and manuscript preparation occurred from January 2015 through February 2018.
Inclusions were (1) age 55 to 89 years; (2) OSA defined as an apnea-hypopnea index (AHI) of 10 or higher, using either split-or whole-night polysomnography. We chose an AHI cutoff of 10 or higher as opposed to 15 or higher, the conventional cutoff for moderate OSA, because split-night studies underestimate the AHI 7 ; (3) amnestic MCI (single and multiple domain) based on Peterson criteria and decision rules [8] [9] [10] : (a) memory complaint, verified by informant; (b) 0 to 0. 5 ; (e) performance approximately 1.0 to 1.5 SDs below normal (adjusted for age and education) in no more than one cognitive domain in addition to memory; (4) medications stable for at least 4 weeks; washout from psychoactive medications for 4 weeks; (5) score of 28 or lower on the 21-item Beck Depression Inventory II 14 ; (6) a study partner; and (7) six or more grades of education or a history to exclude intellectual disability.
Exclusions were (1) significant neurologic disease other than MCI; (2) magnetic resonance imaging (MRI) exclusions (eg, metal); (3) psychiatric disorders (eg, uncontrolled major depression); (4) history of alcohol dependence within 6 months; (5) unstable medical condition; (6) participation in studies involving neuropsychological testing; (7) currently receiving CPAP; (8) requiring oxygen; and (9) dementia indicated by impairment in three to five age-and education-adjusted cognitive domains.
Obstructive sleep apnea measures

Polysomnography
All participants underwent either a full-night diagnostic polysomnography and a full-night CPAP titration or a splitnight diagnostic and CPAP titration polysomnography in an accredited in-laboratory setting. Polysomnography was performed in accordance with the American Academy of Sleep Medicine guidelines. 15 
CPAP adherence and attention control interventions
Project staff provided each participant with a comprehensive CPAP adherence intervention. If at any time during the 1-year study, participants elected not to continue to try to use CPAP or their CPAP unit was taken away by their insurance company for nonuse, staff provided an attention control intervention (Supplementary Table S1 ).
Outcome measures and blinding
The neuropsychological testers were blinded to group membership. They measured outcomes at baseline, 6 months, and 1 year.
Primary outcomes
Cognitive function. Memory was measured with the Hopkins Verbal Learning Test-Revised (HVLT-R) total recall, 16 and psychomotor/cognitive processing speed was measured with the Digit Symbol (DS) subtest from the Wechsler Adult Intelligence Scale age-adjusted total scaled score. 17, 18 Secondary cognitive function outcomes. Global cognition was assessed with the MMSE. Attention was measured with the Stroop Color and Word test 19 and the Psychomotor Vigilance Task 20 transformed number of lapses. Daytime sleepiness was measured with the Epworth Sleepiness Scale. 21 
Secondary outcomes
Everyday function and progression. Function was measured with the study partner rated Everyday Cognition 22 and the OSA-specific Functional Outcomes of Sleep Questionnaire. 23 Participants' view of change at 1 year was measured with the Alzheimer's Disease Cooperative StudyClinical Global Impression of Change (ADCS-CGIC) scale. 24 Progression was assessed with the CDR.
Sample size
The pilot study was prospectively powered to detect a significant difference in the HVLT-R. Because no similar studies had been done, estimates were based on a study of older adults with AD and OSA 25 and assumed a mean score of 8.0 at baseline for the HVLT-R, with an SD of 2.4. As such, 35 participants in the MCI −CPAP group and 75 participants in the MCI +CPAP group achieved 81% power to detect a 1-unit improvement in the HVLT-R. Although we were unable to recruit the desired sample size, 29 in the MCI +CPAP group, 25 in the MCI −CPAP group was sufficient to show a significant difference in the secondary cognitive function outcome and allowed ES estimates for a larger study. 
Statistical analysis
Differences in baseline characteristics between the MCI −CPAP and the MCI +CPAP adherence groups were examined. Within-group changes from baseline to 6 months and baseline to 1 year were evaluated. Separate unadjusted and adjusted general linear models were generated for change from baseline to 6 months and baseline to 1 year, where the outcome was regressed on adherence group. Model assumptions were assessed; to protect against violations in the homoscedasticity assumption, the robust variance estimator (Huber Sandwich Estimator) was used to estimate the variance of the maximum likelihood estimates. Adherence group differences in least square mean estimates, divided by the estimated variation obtained using mean square error, were used to estimate between-group ESs using the adjusted general linear model results. Separate unadjusted and adjusted logistic regression models were generated for improvement on the CDR and ADCS-CGIC, where each outcome was regressed on adherence group. All regression models were adjusted for age, race, and marital status to account for significant baseline group differences. Statistical significance was at the .05 level. Analyses were performed with SAS software, v.9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Participants
There were 68 MCI +OSA participants at baseline, and 14 (21%) dropped out during the 1-year follow-up (Supplementary Figure S1) . We compared the dropouts with completers on age, sex, marital status, education, race, OSA severity, apolipoprotein E (ApoE4), cognition-enhancing medications, cognitive and everyday function, and daytime sleepiness. The only differences were in ApoE4 genotype and marital status. Participants were more likely to drop out if they were ApoE4 negative (<.001). Those who were married were more likely to stay in the study (p = .01), and marital status was used as a covariate in general linear modeling. For the total sample, the mean age was 70.1 AE 8.3 years, 44.4% were female, and 64.8% were white. The MCI −CPAP group was significantly older; and significantly fewer were white and married (Table 1) . Potential adverse events occurred in five participants without any permanent sequelae, all of whom were in the MCI +CPAP group, but none were deemed to be treatment related.
The 6-month and 1-year outcomes
In the MCI +CPAP group, significant increases in psychomotor/cognitive processing (DS) were observed from baseline to 6 months (change = 0.64) and baseline to 1 year (change = 1.02) ( Table 2 ). There were also significant decreases in daytime sleepiness in the MCI +CPAP group from baseline to 6 months (change = −1.96) and baseline to 1 year (change = −2.12). In the MCI −CPAP group, attention significantly improved from baseline to 6 months (change = −2.23) and baseline to 1 year (change = −1.66). Significant decreases in global cognition were observed from baseline to 1 year (change = −1.61) in the MCI −CPAP group. Table 3 summarizes the unadjusted and adjusted general linear regression model results for the change in outcomes from baseline to 1 year. Statistically significant improvements in psychomotor/cognitive processing speed in the MCI +CPAP group vs the MCI −CPAP group were observed at 1 year after adjustment for age, race, and marital status (Table 3; Data on the CDR were missing in 12 individuals because we were unable to contact their study partners before study closure. During the 1-year study, 21 participants improved on the CDR; 21 worsened or stayed the same. The MCI +CPAP group had more than a 2-fold increased odds of improving on the CDR as compared with the MCI −CPAP group, adjusting for age, race, and marital status (odds ratio [OR] = 2.16]; 95% CI = 0.38-12.42; p = .39). Data were missing on the ADCS-CGIC in 12 individuals because data were not collected (n = 12). Overall, 34 participants rated themselves as improving over 1 year, and 7 reported that they had worsened or were unchanged. The MCI +CPAP group demonstrated an over 5-fold increased odds of improving on the ADCS-CGIC self-report as compared with the MCI −CPAP group, adjusting for age, race, and marital status (OR = 5.31; 95% CI = 0.63-44.86; p = .12) (Supplementary Table S2 ). The findings from these logistic regression models are clinically important but not statistically significant due to our small sample size. 
DISCUSSION
Our research revealed a statistically significant beneficial effect of CPAP adherence, controlling for age, race, and marital status, on psychomotor/cognitive processing speed with a moderate to large ES at 1 year, and small to moderate effect sizes across multiple domains of cognitive function in persons with MCI and OSA. Although this was a pilot study, our data show a pattern of benefits for CPAP adherence in older adults with MCI and OSA. A larger adequately powered study is needed to confirm our findings. Strengths of this research include recruitment from diverse settings, a well-characterized sample, equal attention to both groups, blinding of the outcome assessors to adherence data, a low trial attrition, and 1-year follow-up. Although we compared the MCI +CPAP and the MCI −CPAP groups on 22 potential baseline confounders, and controlled for the differences in our analysis, the groups may have been different on unidentified variables that may have affected the study outcomes. Like others, 26 we found that whites were more likely to adhere to CPAP, and we controlled for race in the data analysis. We also controlled for marital status. The MCI +CPAP group involved more married/cohabitating participants that may contribute to CPAP adherence 27 and may protect against cognitive decline.
28
Frequent phone calls and a newsletter resulted in a good 1-year participant retention, but 22% of participants had missing 12-month CDR data because study partners were unavailable. Future studies might compensate study partners. Investigators also should consider measuring amyloid burden and total sleep time using actigraphy to determine if there are differences at baseline between adherence groups. We based our definition of CPAP adherence on evidence-based recommendations, 29 but a higher mean CPAP use over 1 year might have had a larger effect. 30 In general, our sample was not excessively sleepy. However, future larger studies might examine changes in neurocognitive function related to CPAP adherence in those with and without excessive daytime sleepiness. We anticipated that CPAP adherence would result in larger effects on HVLT-R memory. Mean scores, however, changed little over 1 year in both study groups, indicating that the HVLT may not be a sensitive measure of memory over 1 year in this population.
The DS is sensitive to many conditions that influence cognitive performance, but it has not been shown to be a specific indicator of cognitive function or changes in cognitive function in persons with MCI. However, in our study, it was quite sensitive to differences in CPAP adherence and had larger ESs than other cognitive measures at both 6 months and 1 year. The DS taps an informationprocessing inefficiency that may be a central feature of the cognitive deficit in persons with MCI +OSA. Future studies might use implicit learning tests to assess the recall of symbol-digit relations to help determine the role that subprocesses might play in coding tasks or regression-based approaches in which coding performance is correlated with additional neuropsychological tests that assess specific cognitive domains.
To our knowledge, Memories 1 is the first prospective clinical trial to show that CPAP adherence in MCI +OSA significantly improves cognitive function. Further, although not statistically significant because of the pilot nature of this study, the MCI +CPAP group reported an over 5-fold increased odds (p = .12) of perceiving that they had improved, as compared with the MCI −CPAP group, and this is important from a clinical perspective because it represents an outcome that matters to individuals. 5 Clinicians should screen for OSA in older adults with MCI and treat it.
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